These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23879911)

  • 41. What are the consequences if i postpone treatment of my PSA-detected prostate cancer?
    Sampson JN
    Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):727-8. PubMed ID: 21546364
    [No Abstract]   [Full Text] [Related]  

  • 42. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
    Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
    Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?
    Gosselaar C; Roobol MJ; Schröder FH
    BJU Int; 2005 Feb; 95(2):231-7. PubMed ID: 15667646
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [How to select the best candidates for prostate biopsies? The role of traditional tools and contribution of new biomarkers in prostate cancer].
    Audenet F; Rouprêt M; Perrin P; de La Taille A
    Prog Urol; 2011 May; 21 Suppl 3():S88-92. PubMed ID: 21616446
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage.
    Grasso YZ; Gupta MK; Levin HS; Zippe CD; Klein EA
    Cancer Res; 1998 Apr; 58(7):1456-9. PubMed ID: 9537248
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Editorial comment.
    Phillips J
    J Urol; 2014 Dec; 192(6):1649; discussion 1649. PubMed ID: 25194544
    [No Abstract]   [Full Text] [Related]  

  • 47. Editorial comment.
    Ukimura O
    J Urol; 2014 Dec; 192(6):1648; discussion 1649. PubMed ID: 25194546
    [No Abstract]   [Full Text] [Related]  

  • 48. Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy.
    Miyakubo M; Ito K; Yamamoto T; Takechi H; Ohi M; Suzuki K
    Int J Urol; 2009 Jun; 16(6):561-5. PubMed ID: 19456991
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: a multicenter study.
    Yang WJ; Lee DH; Chung BH; Cho JS; Choi YD; Kim SJ; Cho IR; Kim HS; Kim CI; Hong SJ;
    Urology; 2006 Feb; 67(2):333-6. PubMed ID: 16461083
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Body mass index in relation to serum prostate-specific antigen levels and prostate cancer risk.
    Bonn SE; Sjölander A; Tillander A; Wiklund F; Grönberg H; Bälter K
    Int J Cancer; 2016 Jul; 139(1):50-7. PubMed ID: 26914149
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection.
    Freedland SJ; Platz EA; Presti JC; Aronson WJ; Amling CL; Kane CJ; Terris MK
    J Urol; 2006 Feb; 175(2):500-4; discussion 504. PubMed ID: 16406980
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [PSA level--is 4.0 ng/ml as upper limit too high].
    Aktuelle Urol; 2005 Jun; 36(3):181-8. PubMed ID: 16001334
    [No Abstract]   [Full Text] [Related]  

  • 53. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Some concerns about prostate cancer location, Gleason grade, and postradiation doubling times.
    Stamey TA
    Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):967-8; discussion 972. PubMed ID: 7591913
    [No Abstract]   [Full Text] [Related]  

  • 55. Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.
    Kawamura K; Suzuki H; Kamiya N; Imamoto T; Yano M; Miura J; Shimbo M; Suzuki N; Nakatsu H; Ichikawa T
    Int J Urol; 2008 Jul; 15(7):598-603. PubMed ID: 18462353
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prostatic meningeal carcinomatosis with low serum level of prostate-specific antigen.
    Honda M; Miyagawa I
    Urology; 2005 Dec; 66(6):1320. PubMed ID: 16360475
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prostate-specific Antigen Mass Density--A Measure Predicting Prostate Cancer Volume and Accounting for Overweight and Obesity-related Prostate-specific Antigen Hemodilution.
    Kryvenko ON; Diaz M; Matoso A; Kates M; Cohen J; Swanson GP; Epstein JI
    Urology; 2016 Apr; 90():141-7. PubMed ID: 26773349
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PSA/prostate volume ratio.
    Vesey SG
    Br J Urol; 1994 Nov; 74(5):682-3. PubMed ID: 7530130
    [No Abstract]   [Full Text] [Related]  

  • 59. Prostate cancer: why is PSA velocity such a sticky concept?
    Vickers AJ
    Nat Rev Urol; 2013 Apr; 10(4):189-90. PubMed ID: 23478537
    [No Abstract]   [Full Text] [Related]  

  • 60. Management of rising prostate-specific antigen following a negative biopsy.
    Jones JS
    Curr Opin Urol; 2010 May; 20(3):198-203. PubMed ID: 20583345
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.